AI Robotics in Medicine

Digital health is splitting between consumer-first telehealth and AI-enabled precision medicine, with performance and valuations moving in opposite directions. Over the past three months HIMS gained 51.

9% while TEM fell 13. 8%, yet both are down year-over-year (-53.

1% vs -13. 6%); HIMS trades at 1.

7x forward sales versus TEM’s 4. 8x (Medical sector: 2.

1x), and their Value Scores are D and F—signaling investors are choosing between accessibility-driven subscription scale and data-heavy platforms for diagnostics, genomics, and clinical decision support.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

1. Hims & Hers Outpaces Tempus AI as Valuations Contrast Sharply

Hims & Hers and Tempus AI represent diverging models in digital health: consumer telehealth versus AI-driven precision medicine. In the last three months, HIMS gained 51.

9% while TEM fell 13. 8%, though over the past year HIMS dropped 53.

1% versus TEM’s 13. 6% decline.

Valuation also diverges: HIMS trades at 1. 7x forward sales, below its two-year median 3x, while TEM is at 4.

8x, below its 7. 9x median.

Against the Medical sector’s 2. 1x forward P/S, HIMS “appears cheap” and TEM “seems expensive,” and their Value Scores sit at D and F, respectively.

The snapshot underscores a trade-off between accessibility-focused, subscription telehealth and data-heavy platforms powering diagnostics, genomics, and clinical decision support.

As digital health and AI integration accelerate, investors are choosing between consumer-first telehealth and AI-enabled precision medicine infrastructure.

Key facts:

- HIMS rose 51.9% in three months; TEM fell 13.8% over the same period.

- Over the past year, HIMS fell 53.1% and TEM declined 13.6%.

- HIMS trades at 1.7x forward P/S, below its two-year median of 3x.

- TEM trades at 4.8x forward P/S, below its two-year median of 7.9x.

- Medical sector average forward P/S is 2.1x; HIMS appears cheap, TEM expensive.

Why it matters: This pits two AI healthcare bets against each other: scalable DTC telehealth subscriptions versus AI-enabled precision medicine for clinicians and researchers.

Valuation spreads suggest differing risk appetites, with HIMS screening cheaper than the sector and TEM richer.

As AI and digital care adoption accelerate, relative performance may hinge on traction in subscription-based telehealth versus demand for diagnostics, genomics, and data analytics.

Finance